Predictive biomarkers market seen reaching $25.65 billion by 2030

The predictive biomarkers market is projected to grow from $20.96 billion in 2025 to $25.65 billion by 2030, driven by cancer prevalence, personalized medicine and expanding molecular diagnostics. North America led in 2025, while Europe is forecast to be the fastest-growing region.

Why it matters: - Predictive biomarkers help identify which patients are most likely to develop disease or respond to a treatment. - The market’s growth reflects rising demand for more personalized care in oncology and other areas. - The category matters to drug makers, diagnostics firms and health systems trying to improve treatment success rates and reduce adverse effects.

What happened: - The predictive biomarkers market is valued at $20.96 billion in 2025. - The market is expected to rise to $21.88 billion in 2026, a 4.4% increase. - The market is forecast to reach $25.65 billion by 2030, growing at a 4.0% compound annual growth rate. - The Business Research Company released the market research with a focus on growth drivers, regional trends and future opportunities. - The company also offered a free sample of the report and the full market report.

The details: - Growth over the next several years is tied to genomic research, targeted therapies, expanding molecular diagnostic tools and supportive regulatory frameworks. - Future expansion is expected to come from multi-omics technologies, personalized medicine, higher pharmaceutical R&D spending, stronger demand for predictive treatment outcomes and wider use of biomarkers in routine care. - The report points to precision oncology, drug response stratification, biomarker-guided clinical trials, companion diagnostics and biomarker validation standards as key trends. - Predictive biomarkers can be genetic, proteomic or molecular indicators. - These markers are used to assess disease susceptibility and treatment effectiveness. - Cancer is a major demand driver because rising case counts increase the need for tools that can guide targeted therapy. - In April 2024, the International Agency for Research on Cancer reported nearly 20 million new cancer cases and about 10 million cancer-related deaths in 2022. - The same agency projected new cancer cases could reach 35 million a year by 2050, a 77% increase from 2022.

Between the lines: - The market forecast suggests biomarker testing is moving from specialized research into more routine clinical use. - The emphasis on companion diagnostics and trial design points to closer ties between diagnostics development and drug development. - North America held the largest market share in 2025, which signals the region’s established biotech and healthcare infrastructure. - Europe is expected to grow the fastest during the forecast period, indicating room for catch-up adoption and policy support. - The report’s expanded 2026 features, including TAM analysis, company scoring matrices and market hotspot graphics, suggest buyers want more decision-ready intelligence rather than raw market data.

What's next: - Biomarker adoption is likely to increase as pharmaceutical companies push more personalized therapies through development. - More clinical programs are expected to use biomarkers to identify likely responders earlier in the treatment process. - Regional competition may intensify as Europe accelerates growth and other markets expand their diagnostic capabilities. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring graphics, Excel dashboards and trend analysis.